nodes	percent_of_prediction	percent_of_DWPC	metapath
Ceftazidime—SLC15A1—Lisinopril—systemic scleroderma	0.333	0.436	CbGbCtD
Ceftazidime—SLC15A1—Captopril—systemic scleroderma	0.249	0.327	CbGbCtD
Ceftazidime—SLC22A6—Captopril—systemic scleroderma	0.137	0.18	CbGbCtD
Ceftazidime—SLC22A6—Methotrexate—systemic scleroderma	0.0433	0.0568	CbGbCtD
Ceftazidime—Angiopathy—Mycophenolic acid—systemic scleroderma	0.00057	0.0024	CcSEcCtD
Ceftazidime—Anaphylactic shock—Captopril—systemic scleroderma	0.000567	0.00239	CcSEcCtD
Ceftazidime—Hallucination—Lisinopril—systemic scleroderma	0.000563	0.00237	CcSEcCtD
Ceftazidime—Dysgeusia—Leflunomide—systemic scleroderma	0.000561	0.00236	CcSEcCtD
Ceftazidime—Thrombophlebitis—Prednisone—systemic scleroderma	0.000561	0.00236	CcSEcCtD
Ceftazidime—Vaginal inflammation—Methotrexate—systemic scleroderma	0.000559	0.00235	CcSEcCtD
Ceftazidime—Thrombocytopenia—Captopril—systemic scleroderma	0.000556	0.00234	CcSEcCtD
Ceftazidime—Pain—Mometasone—systemic scleroderma	0.000552	0.00232	CcSEcCtD
Ceftazidime—Infestation—Mycophenolate mofetil—systemic scleroderma	0.000552	0.00232	CcSEcCtD
Ceftazidime—Infestation NOS—Mycophenolate mofetil—systemic scleroderma	0.000552	0.00232	CcSEcCtD
Ceftazidime—Hypersensitivity—Pentoxifylline—systemic scleroderma	0.000552	0.00232	CcSEcCtD
Ceftazidime—Leukopenia—Azathioprine—systemic scleroderma	0.000543	0.00228	CcSEcCtD
Ceftazidime—Renal failure—Mycophenolate mofetil—systemic scleroderma	0.000543	0.00228	CcSEcCtD
Ceftazidime—Vision blurred—Leflunomide—systemic scleroderma	0.00054	0.00227	CcSEcCtD
Ceftazidime—Jaundice—Mycophenolate mofetil—systemic scleroderma	0.000538	0.00226	CcSEcCtD
Ceftazidime—Erythema multiforme—Lisinopril—systemic scleroderma	0.000535	0.00225	CcSEcCtD
Ceftazidime—Skin exfoliation—Methotrexate—systemic scleroderma	0.000534	0.00224	CcSEcCtD
Ceftazidime—Hypotension—Captopril—systemic scleroderma	0.00053	0.00223	CcSEcCtD
Ceftazidime—Pruritus—Pentoxifylline—systemic scleroderma	0.00053	0.00223	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Mometasone—systemic scleroderma	0.000528	0.00222	CcSEcCtD
Ceftazidime—Vaginal infection—Methotrexate—systemic scleroderma	0.000528	0.00222	CcSEcCtD
Ceftazidime—Flushing—Lisinopril—systemic scleroderma	0.000525	0.00221	CcSEcCtD
Ceftazidime—Aplastic anaemia—Methotrexate—systemic scleroderma	0.000525	0.00221	CcSEcCtD
Ceftazidime—Angioedema—Leflunomide—systemic scleroderma	0.000524	0.0022	CcSEcCtD
Ceftazidime—Hepatobiliary disease—Mycophenolate mofetil—systemic scleroderma	0.000522	0.0022	CcSEcCtD
Ceftazidime—Vision blurred—Mycophenolic acid—systemic scleroderma	0.000515	0.00217	CcSEcCtD
Ceftazidime—Agranulocytosis—Mycophenolate mofetil—systemic scleroderma	0.000515	0.00217	CcSEcCtD
Ceftazidime—Angiopathy—Lisinopril—systemic scleroderma	0.000513	0.00216	CcSEcCtD
Ceftazidime—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—systemic scleroderma	0.000513	0.00216	CcSEcCtD
Ceftazidime—Leukopenia—Leflunomide—systemic scleroderma	0.000513	0.00216	CcSEcCtD
Ceftazidime—Diarrhoea—Pentoxifylline—systemic scleroderma	0.000512	0.00215	CcSEcCtD
Ceftazidime—Tremor—Mycophenolic acid—systemic scleroderma	0.000512	0.00215	CcSEcCtD
Ceftazidime—Coma—Methotrexate—systemic scleroderma	0.000511	0.00215	CcSEcCtD
Ceftazidime—Abdominal pain—Mometasone—systemic scleroderma	0.000511	0.00215	CcSEcCtD
Ceftazidime—Body temperature increased—Mometasone—systemic scleroderma	0.000511	0.00215	CcSEcCtD
Ceftazidime—Paraesthesia—Captopril—systemic scleroderma	0.00051	0.00214	CcSEcCtD
Ceftazidime—Agitation—Mycophenolic acid—systemic scleroderma	0.000502	0.00211	CcSEcCtD
Ceftazidime—Haemoglobin—Mycophenolate mofetil—systemic scleroderma	0.000498	0.00209	CcSEcCtD
Ceftazidime—Haemorrhage—Mycophenolate mofetil—systemic scleroderma	0.000496	0.00208	CcSEcCtD
Ceftazidime—Lethargy—Prednisone—systemic scleroderma	0.000496	0.00208	CcSEcCtD
Ceftazidime—Dizziness—Pentoxifylline—systemic scleroderma	0.000495	0.00208	CcSEcCtD
Ceftazidime—Hallucination—Mycophenolate mofetil—systemic scleroderma	0.000493	0.00207	CcSEcCtD
Ceftazidime—Leukopenia—Mycophenolic acid—systemic scleroderma	0.000489	0.00206	CcSEcCtD
Ceftazidime—Thrombocytopenia—Azathioprine—systemic scleroderma	0.000485	0.00204	CcSEcCtD
Ceftazidime—Unspecified disorder of skin and subcutaneous tissue—Leflunomide—systemic scleroderma	0.000484	0.00204	CcSEcCtD
Ceftazidime—Dysgeusia—Lisinopril—systemic scleroderma	0.000482	0.00203	CcSEcCtD
Ceftazidime—Skin disorder—Azathioprine—systemic scleroderma	0.000481	0.00202	CcSEcCtD
Ceftazidime—Vomiting—Pentoxifylline—systemic scleroderma	0.000476	0.002	CcSEcCtD
Ceftazidime—Convulsion—Mycophenolic acid—systemic scleroderma	0.000474	0.00199	CcSEcCtD
Ceftazidime—Rash—Pentoxifylline—systemic scleroderma	0.000472	0.00199	CcSEcCtD
Ceftazidime—Dermatitis—Pentoxifylline—systemic scleroderma	0.000472	0.00198	CcSEcCtD
Ceftazidime—Headache—Pentoxifylline—systemic scleroderma	0.000469	0.00197	CcSEcCtD
Ceftazidime—Thrombophlebitis—Methotrexate—systemic scleroderma	0.000469	0.00197	CcSEcCtD
Ceftazidime—Anaphylactic shock—Leflunomide—systemic scleroderma	0.000468	0.00197	CcSEcCtD
Ceftazidime—Vision blurred—Lisinopril—systemic scleroderma	0.000464	0.00195	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Captopril—systemic scleroderma	0.000464	0.00195	CcSEcCtD
Ceftazidime—Hypotension—Azathioprine—systemic scleroderma	0.000463	0.00195	CcSEcCtD
Ceftazidime—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—systemic scleroderma	0.000462	0.00194	CcSEcCtD
Ceftazidime—Tremor—Lisinopril—systemic scleroderma	0.000461	0.00194	CcSEcCtD
Ceftazidime—Nervous system disorder—Leflunomide—systemic scleroderma	0.000459	0.00193	CcSEcCtD
Ceftazidime—Thrombocytopenia—Leflunomide—systemic scleroderma	0.000458	0.00193	CcSEcCtD
Ceftazidime—Pruritus—Mometasone—systemic scleroderma	0.000457	0.00192	CcSEcCtD
Ceftazidime—Skin disorder—Leflunomide—systemic scleroderma	0.000454	0.00191	CcSEcCtD
Ceftazidime—Angioedema—Lisinopril—systemic scleroderma	0.00045	0.00189	CcSEcCtD
Ceftazidime—Angiopathy—Mycophenolate mofetil—systemic scleroderma	0.00045	0.00189	CcSEcCtD
Ceftazidime—Abdominal pain—Captopril—systemic scleroderma	0.000449	0.00189	CcSEcCtD
Ceftazidime—Body temperature increased—Captopril—systemic scleroderma	0.000449	0.00189	CcSEcCtD
Ceftazidime—Nausea—Pentoxifylline—systemic scleroderma	0.000445	0.00187	CcSEcCtD
Ceftazidime—Diarrhoea—Mometasone—systemic scleroderma	0.000442	0.00186	CcSEcCtD
Ceftazidime—Leukopenia—Lisinopril—systemic scleroderma	0.000441	0.00185	CcSEcCtD
Ceftazidime—Nervous system disorder—Mycophenolic acid—systemic scleroderma	0.000438	0.00184	CcSEcCtD
Ceftazidime—Hypotension—Leflunomide—systemic scleroderma	0.000437	0.00184	CcSEcCtD
Ceftazidime—Thrombocytopenia—Mycophenolic acid—systemic scleroderma	0.000437	0.00184	CcSEcCtD
Ceftazidime—Skin disorder—Mycophenolic acid—systemic scleroderma	0.000433	0.00182	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.000428	0.0018	CcSEcCtD
Ceftazidime—Dysgeusia—Mycophenolate mofetil—systemic scleroderma	0.000422	0.00178	CcSEcCtD
Ceftazidime—Paraesthesia—Leflunomide—systemic scleroderma	0.00042	0.00177	CcSEcCtD
Ceftazidime—Hypotension—Mycophenolic acid—systemic scleroderma	0.000417	0.00175	CcSEcCtD
Ceftazidime—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.000416	0.00175	CcSEcCtD
Ceftazidime—Lethargy—Methotrexate—systemic scleroderma	0.000414	0.00174	CcSEcCtD
Ceftazidime—Vomiting—Mometasone—systemic scleroderma	0.000411	0.00173	CcSEcCtD
Ceftazidime—Rash—Mometasone—systemic scleroderma	0.000407	0.00171	CcSEcCtD
Ceftazidime—Dermatitis—Mometasone—systemic scleroderma	0.000407	0.00171	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.000405	0.0017	CcSEcCtD
Ceftazidime—Headache—Mometasone—systemic scleroderma	0.000405	0.0017	CcSEcCtD
Ceftazidime—Tremor—Mycophenolate mofetil—systemic scleroderma	0.000404	0.0017	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.000404	0.0017	CcSEcCtD
Ceftazidime—Anaphylactic shock—Lisinopril—systemic scleroderma	0.000402	0.00169	CcSEcCtD
Ceftazidime—Pruritus—Captopril—systemic scleroderma	0.000401	0.00169	CcSEcCtD
Ceftazidime—Paraesthesia—Mycophenolic acid—systemic scleroderma	0.000401	0.00168	CcSEcCtD
Ceftazidime—Pain—Leflunomide—systemic scleroderma	0.0004	0.00168	CcSEcCtD
Ceftazidime—Agitation—Mycophenolate mofetil—systemic scleroderma	0.000396	0.00167	CcSEcCtD
Ceftazidime—Angioedema—Mycophenolate mofetil—systemic scleroderma	0.000394	0.00166	CcSEcCtD
Ceftazidime—Thrombocytopenia—Lisinopril—systemic scleroderma	0.000393	0.00165	CcSEcCtD
Ceftazidime—Neutropenia—Prednisone—systemic scleroderma	0.000392	0.00165	CcSEcCtD
Ceftazidime—Body temperature increased—Azathioprine—systemic scleroderma	0.000391	0.00165	CcSEcCtD
Ceftazidime—Abdominal pain—Azathioprine—systemic scleroderma	0.000391	0.00165	CcSEcCtD
Ceftazidime—Skin disorder—Lisinopril—systemic scleroderma	0.00039	0.00164	CcSEcCtD
Ceftazidime—Diarrhoea—Captopril—systemic scleroderma	0.000388	0.00163	CcSEcCtD
Ceftazidime—Leukopenia—Mycophenolate mofetil—systemic scleroderma	0.000386	0.00162	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000385	0.00162	CcSEcCtD
Ceftazidime—Nausea—Mometasone—systemic scleroderma	0.000384	0.00161	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000382	0.00161	CcSEcCtD
Ceftazidime—Pain—Mycophenolic acid—systemic scleroderma	0.000382	0.0016	CcSEcCtD
Ceftazidime—Hypotension—Lisinopril—systemic scleroderma	0.000375	0.00158	CcSEcCtD
Ceftazidime—Dizziness—Captopril—systemic scleroderma	0.000375	0.00158	CcSEcCtD
Ceftazidime—Convulsion—Mycophenolate mofetil—systemic scleroderma	0.000374	0.00157	CcSEcCtD
Ceftazidime—Urticaria—Leflunomide—systemic scleroderma	0.000372	0.00156	CcSEcCtD
Ceftazidime—Abdominal pain—Leflunomide—systemic scleroderma	0.00037	0.00155	CcSEcCtD
Ceftazidime—Body temperature increased—Leflunomide—systemic scleroderma	0.00037	0.00155	CcSEcCtD
Ceftazidime—Toxic epidermal necrolysis—Methotrexate—systemic scleroderma	0.000365	0.00154	CcSEcCtD
Ceftazidime—Hypersensitivity—Azathioprine—systemic scleroderma	0.000365	0.00153	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000365	0.00153	CcSEcCtD
Ceftazidime—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000365	0.00153	CcSEcCtD
Ceftazidime—Paraesthesia—Lisinopril—systemic scleroderma	0.000361	0.00152	CcSEcCtD
Ceftazidime—Vomiting—Captopril—systemic scleroderma	0.000361	0.00152	CcSEcCtD
Ceftazidime—Rash—Captopril—systemic scleroderma	0.000358	0.0015	CcSEcCtD
Ceftazidime—Dermatitis—Captopril—systemic scleroderma	0.000357	0.0015	CcSEcCtD
Ceftazidime—Headache—Captopril—systemic scleroderma	0.000355	0.00149	CcSEcCtD
Ceftazidime—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000353	0.00148	CcSEcCtD
Ceftazidime—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000353	0.00148	CcSEcCtD
Ceftazidime—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.000352	0.00148	CcSEcCtD
Ceftazidime—Eosinophilia—Methotrexate—systemic scleroderma	0.000347	0.00146	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000347	0.00146	CcSEcCtD
Ceftazidime—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000345	0.00145	CcSEcCtD
Ceftazidime—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000345	0.00145	CcSEcCtD
Ceftazidime—Hypersensitivity—Leflunomide—systemic scleroderma	0.000345	0.00145	CcSEcCtD
Ceftazidime—Pain—Lisinopril—systemic scleroderma	0.000344	0.00144	CcSEcCtD
Ceftazidime—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000342	0.00144	CcSEcCtD
Ceftazidime—Diarrhoea—Azathioprine—systemic scleroderma	0.000339	0.00142	CcSEcCtD
Ceftazidime—Haemoglobin—Prednisone—systemic scleroderma	0.000338	0.00142	CcSEcCtD
Ceftazidime—Nausea—Captopril—systemic scleroderma	0.000337	0.00142	CcSEcCtD
Ceftazidime—Haemorrhage—Prednisone—systemic scleroderma	0.000336	0.00141	CcSEcCtD
Ceftazidime—Hallucination—Prednisone—systemic scleroderma	0.000334	0.00141	CcSEcCtD
Ceftazidime—Pancytopenia—Methotrexate—systemic scleroderma	0.000333	0.0014	CcSEcCtD
Ceftazidime—Pruritus—Leflunomide—systemic scleroderma	0.000331	0.00139	CcSEcCtD
Ceftazidime—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.000329	0.00138	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000329	0.00138	CcSEcCtD
Ceftazidime—Neutropenia—Methotrexate—systemic scleroderma	0.000328	0.00138	CcSEcCtD
Ceftazidime—Dizziness—Azathioprine—systemic scleroderma	0.000327	0.00138	CcSEcCtD
Ceftazidime—Diarrhoea—Leflunomide—systemic scleroderma	0.00032	0.00135	CcSEcCtD
Ceftazidime—Urticaria—Lisinopril—systemic scleroderma	0.000319	0.00134	CcSEcCtD
Ceftazidime—Abdominal pain—Lisinopril—systemic scleroderma	0.000318	0.00134	CcSEcCtD
Ceftazidime—Body temperature increased—Lisinopril—systemic scleroderma	0.000318	0.00134	CcSEcCtD
Ceftazidime—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000316	0.00133	CcSEcCtD
Ceftazidime—Pruritus—Mycophenolic acid—systemic scleroderma	0.000316	0.00133	CcSEcCtD
Ceftazidime—Vomiting—Azathioprine—systemic scleroderma	0.000315	0.00132	CcSEcCtD
Ceftazidime—Infestation NOS—Methotrexate—systemic scleroderma	0.000313	0.00132	CcSEcCtD
Ceftazidime—Infestation—Methotrexate—systemic scleroderma	0.000313	0.00132	CcSEcCtD
Ceftazidime—Rash—Azathioprine—systemic scleroderma	0.000312	0.00131	CcSEcCtD
Ceftazidime—Dermatitis—Azathioprine—systemic scleroderma	0.000312	0.00131	CcSEcCtD
Ceftazidime—Flushing—Prednisone—systemic scleroderma	0.000312	0.00131	CcSEcCtD
Ceftazidime—Headache—Azathioprine—systemic scleroderma	0.00031	0.0013	CcSEcCtD
Ceftazidime—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	0.00031	0.0013	CcSEcCtD
Ceftazidime—Dizziness—Leflunomide—systemic scleroderma	0.000309	0.0013	CcSEcCtD
Ceftazidime—Renal failure—Methotrexate—systemic scleroderma	0.000307	0.00129	CcSEcCtD
Ceftazidime—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000305	0.00128	CcSEcCtD
Ceftazidime—Angiopathy—Prednisone—systemic scleroderma	0.000305	0.00128	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000304	0.00128	CcSEcCtD
Ceftazidime—Immune system disorder—Prednisone—systemic scleroderma	0.000303	0.00128	CcSEcCtD
Ceftazidime—Pain—Mycophenolate mofetil—systemic scleroderma	0.000301	0.00127	CcSEcCtD
Ceftazidime—Vomiting—Leflunomide—systemic scleroderma	0.000297	0.00125	CcSEcCtD
Ceftazidime—Hypersensitivity—Lisinopril—systemic scleroderma	0.000296	0.00124	CcSEcCtD
Ceftazidime—Hepatobiliary disease—Methotrexate—systemic scleroderma	0.000296	0.00124	CcSEcCtD
Ceftazidime—Dizziness—Mycophenolic acid—systemic scleroderma	0.000295	0.00124	CcSEcCtD
Ceftazidime—Rash—Leflunomide—systemic scleroderma	0.000295	0.00124	CcSEcCtD
Ceftazidime—Dermatitis—Leflunomide—systemic scleroderma	0.000295	0.00124	CcSEcCtD
Ceftazidime—Nausea—Azathioprine—systemic scleroderma	0.000294	0.00124	CcSEcCtD
Ceftazidime—Headache—Leflunomide—systemic scleroderma	0.000293	0.00123	CcSEcCtD
Ceftazidime—Agranulocytosis—Methotrexate—systemic scleroderma	0.000292	0.00123	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000288	0.00121	CcSEcCtD
Ceftazidime—Pruritus—Lisinopril—systemic scleroderma	0.000284	0.0012	CcSEcCtD
Ceftazidime—Vomiting—Mycophenolic acid—systemic scleroderma	0.000284	0.00119	CcSEcCtD
Ceftazidime—Haemoglobin—Methotrexate—systemic scleroderma	0.000282	0.00119	CcSEcCtD
Ceftazidime—Rash—Mycophenolic acid—systemic scleroderma	0.000281	0.00118	CcSEcCtD
Ceftazidime—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000281	0.00118	CcSEcCtD
Ceftazidime—Haemorrhage—Methotrexate—systemic scleroderma	0.000281	0.00118	CcSEcCtD
Ceftazidime—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.00028	0.00118	CcSEcCtD
Ceftazidime—Headache—Mycophenolic acid—systemic scleroderma	0.000279	0.00118	CcSEcCtD
Ceftazidime—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000278	0.00117	CcSEcCtD
Ceftazidime—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000278	0.00117	CcSEcCtD
Ceftazidime—Nausea—Leflunomide—systemic scleroderma	0.000278	0.00117	CcSEcCtD
Ceftazidime—Vision blurred—Prednisone—systemic scleroderma	0.000276	0.00116	CcSEcCtD
Ceftazidime—Diarrhoea—Lisinopril—systemic scleroderma	0.000275	0.00116	CcSEcCtD
Ceftazidime—Agitation—Prednisone—systemic scleroderma	0.000269	0.00113	CcSEcCtD
Ceftazidime—Angioedema—Prednisone—systemic scleroderma	0.000267	0.00112	CcSEcCtD
Ceftazidime—Dizziness—Lisinopril—systemic scleroderma	0.000266	0.00112	CcSEcCtD
Ceftazidime—Erythema multiforme—Methotrexate—systemic scleroderma	0.000265	0.00112	CcSEcCtD
Ceftazidime—Nausea—Mycophenolic acid—systemic scleroderma	0.000265	0.00111	CcSEcCtD
Ceftazidime—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000259	0.00109	CcSEcCtD
Ceftazidime—Vomiting—Lisinopril—systemic scleroderma	0.000255	0.00107	CcSEcCtD
Ceftazidime—Angiopathy—Methotrexate—systemic scleroderma	0.000255	0.00107	CcSEcCtD
Ceftazidime—Immune system disorder—Methotrexate—systemic scleroderma	0.000254	0.00107	CcSEcCtD
Ceftazidime—Rash—Lisinopril—systemic scleroderma	0.000253	0.00107	CcSEcCtD
Ceftazidime—Convulsion—Prednisone—systemic scleroderma	0.000253	0.00107	CcSEcCtD
Ceftazidime—Dermatitis—Lisinopril—systemic scleroderma	0.000253	0.00106	CcSEcCtD
Ceftazidime—Headache—Lisinopril—systemic scleroderma	0.000252	0.00106	CcSEcCtD
Ceftazidime—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000249	0.00105	CcSEcCtD
Ceftazidime—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000247	0.00104	CcSEcCtD
Ceftazidime—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000241	0.00101	CcSEcCtD
Ceftazidime—Dysgeusia—Methotrexate—systemic scleroderma	0.000239	0.00101	CcSEcCtD
Ceftazidime—Nausea—Lisinopril—systemic scleroderma	0.000239	0.001	CcSEcCtD
Ceftazidime—Anaphylactic shock—Prednisone—systemic scleroderma	0.000239	0.001	CcSEcCtD
Ceftazidime—Nervous system disorder—Prednisone—systemic scleroderma	0.000234	0.000984	CcSEcCtD
Ceftazidime—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000233	0.000979	CcSEcCtD
Ceftazidime—Skin disorder—Prednisone—systemic scleroderma	0.000232	0.000975	CcSEcCtD
Ceftazidime—Vision blurred—Methotrexate—systemic scleroderma	0.00023	0.000968	CcSEcCtD
Ceftazidime—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000224	0.000941	CcSEcCtD
Ceftazidime—Rash—Mycophenolate mofetil—systemic scleroderma	0.000222	0.000933	CcSEcCtD
Ceftazidime—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000222	0.000933	CcSEcCtD
Ceftazidime—Headache—Mycophenolate mofetil—systemic scleroderma	0.000221	0.000927	CcSEcCtD
Ceftazidime—Leukopenia—Methotrexate—systemic scleroderma	0.000219	0.00092	CcSEcCtD
Ceftazidime—Paraesthesia—Prednisone—systemic scleroderma	0.000214	0.000901	CcSEcCtD
Ceftazidime—Convulsion—Methotrexate—systemic scleroderma	0.000212	0.00089	CcSEcCtD
Ceftazidime—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000209	0.000879	CcSEcCtD
Ceftazidime—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000207	0.000869	CcSEcCtD
Ceftazidime—Anaphylactic shock—Methotrexate—systemic scleroderma	0.000199	0.000839	CcSEcCtD
Ceftazidime—Nervous system disorder—Methotrexate—systemic scleroderma	0.000196	0.000822	CcSEcCtD
Ceftazidime—Thrombocytopenia—Methotrexate—systemic scleroderma	0.000195	0.000821	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000195	0.000821	CcSEcCtD
Ceftazidime—Skin disorder—Methotrexate—systemic scleroderma	0.000194	0.000815	CcSEcCtD
Ceftazidime—Urticaria—Prednisone—systemic scleroderma	0.00019	0.000797	CcSEcCtD
Ceftazidime—Abdominal pain—Prednisone—systemic scleroderma	0.000189	0.000793	CcSEcCtD
Ceftazidime—Body temperature increased—Prednisone—systemic scleroderma	0.000189	0.000793	CcSEcCtD
Ceftazidime—Hypotension—Methotrexate—systemic scleroderma	0.000186	0.000784	CcSEcCtD
Ceftazidime—Paraesthesia—Methotrexate—systemic scleroderma	0.000179	0.000753	CcSEcCtD
Ceftazidime—Hypersensitivity—Prednisone—systemic scleroderma	0.000176	0.000739	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000172	0.000724	CcSEcCtD
Ceftazidime—Pain—Methotrexate—systemic scleroderma	0.000171	0.000717	CcSEcCtD
Ceftazidime—Pruritus—Prednisone—systemic scleroderma	0.000169	0.00071	CcSEcCtD
Ceftazidime—Diarrhoea—Prednisone—systemic scleroderma	0.000163	0.000687	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000163	0.000686	CcSEcCtD
Ceftazidime—Urticaria—Methotrexate—systemic scleroderma	0.000158	0.000666	CcSEcCtD
Ceftazidime—Dizziness—Prednisone—systemic scleroderma	0.000158	0.000664	CcSEcCtD
Ceftazidime—Abdominal pain—Methotrexate—systemic scleroderma	0.000158	0.000663	CcSEcCtD
Ceftazidime—Body temperature increased—Methotrexate—systemic scleroderma	0.000158	0.000663	CcSEcCtD
Ceftazidime—Vomiting—Prednisone—systemic scleroderma	0.000152	0.000638	CcSEcCtD
Ceftazidime—Rash—Prednisone—systemic scleroderma	0.00015	0.000633	CcSEcCtD
Ceftazidime—Dermatitis—Prednisone—systemic scleroderma	0.00015	0.000632	CcSEcCtD
Ceftazidime—Headache—Prednisone—systemic scleroderma	0.00015	0.000629	CcSEcCtD
Ceftazidime—Hypersensitivity—Methotrexate—systemic scleroderma	0.000147	0.000618	CcSEcCtD
Ceftazidime—Nausea—Prednisone—systemic scleroderma	0.000142	0.000596	CcSEcCtD
Ceftazidime—Pruritus—Methotrexate—systemic scleroderma	0.000141	0.000593	CcSEcCtD
Ceftazidime—Diarrhoea—Methotrexate—systemic scleroderma	0.000136	0.000574	CcSEcCtD
Ceftazidime—Dizziness—Methotrexate—systemic scleroderma	0.000132	0.000555	CcSEcCtD
Ceftazidime—Vomiting—Methotrexate—systemic scleroderma	0.000127	0.000533	CcSEcCtD
Ceftazidime—Rash—Methotrexate—systemic scleroderma	0.000126	0.000529	CcSEcCtD
Ceftazidime—Dermatitis—Methotrexate—systemic scleroderma	0.000126	0.000528	CcSEcCtD
Ceftazidime—Headache—Methotrexate—systemic scleroderma	0.000125	0.000525	CcSEcCtD
Ceftazidime—Nausea—Methotrexate—systemic scleroderma	0.000118	0.000498	CcSEcCtD
